|
Market Closed -
Nasdaq
23:00:00 23/10/2026 +03
|
5-day change | 1st Jan Change | ||
| 434.24 USD | -4.21% |
|
-3.45% | -25.43% |
Company Valuation: Madrigal Pharmaceuticals, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 1,449 | 5,179 | 4,568 | 6,730 | 13,226 | 10,033 | - | - |
| Change | - | 257.45% | -11.79% | 47.33% | 96.52% | -24.14% | - | - |
| Enterprise Value (EV) 1 | 1,179 | 4,869 | 4,051 | 5,922 | 12,584 | 9,506 | 9,109 | 8,030 |
| Change | - | 313.04% | -16.81% | 46.21% | 112.48% | -24.46% | -4.18% | -11.84% |
| P/E | -5.79x | -16.8x | -11.6x | -14.1x | -45.3x | -69.4x | 83.4x | 20.8x |
| PBR | 7.15x | 26.6x | 11.3x | 9x | 22.1x | 22.2x | 12.5x | 6.19x |
| PEG | - | -0.9x | -0.7x | -1.48x | 1.1x | 1.4x | -0x | 0x |
| Capitalization / Revenue | - | - | - | 37.4x | 13.8x | 6.57x | 4.73x | 3.5x |
| EV / Revenue | - | - | - | 32.9x | 13.1x | 6.22x | 4.29x | 2.81x |
| EV / EBITDA | -4.87x | -16.6x | -10.7x | -11.9x | -42.1x | -53.5x | 76.2x | 13.8x |
| EV / EBIT | -4.86x | -16.6x | -10.6x | -11.9x | -41.9x | -51.2x | 57.4x | 12.1x |
| EV / FCF | -4.87x | -16.6x | -12.4x | -13x | -66.2x | -47.4x | 33.5x | 10x |
| FCF Yield | -20.6% | -6.01% | -8.04% | -7.72% | -1.51% | -2.11% | 2.99% | 9.98% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | -14.63 | -17.23 | -19.99 | -21.9 | -12.85 | -6.258 | 5.204 | 20.89 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | - | - | - | 180.1 | 958.4 | 1,528 | 2,121 | 2,863 |
| EBITDA 1 | -242.1 | -293.1 | -380 | -496.8 | -298.6 | -177.7 | 119.5 | 582.2 |
| EBIT 1 | -242.5 | -293.6 | -380.5 | -497.9 | -300.1 | -185.8 | 158.7 | 663.3 |
| Net income 1 | -241.8 | -295.4 | -373.6 | -465.9 | -288.3 | -182 | 171.3 | 651.6 |
| Net Debt 1 | -269.9 | -309.5 | -517.5 | -807.7 | -642 | -526.9 | -924 | -2,002 |
| Reference price 2 | 84.74 | 290.25 | 231.38 | 308.57 | 582.34 | 434.24 | 434.24 | 434.24 |
| Nbr of stocks (in thousands) | 17,097 | 17,842 | 19,743 | 21,810 | 22,711 | 23,104 | - | - |
| Announcement Date | 2/24/22 A | 2/23/23 A | 2/28/24 A | 2/26/25 A | 2/19/26 A | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (N) | EV / Sales (N) | EV / EBITDA (N) | Dividend Yield (N) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -69.38x | 6.22x | -53.49x | -.--% | 10.03B | |
| 18.83x | 6.63x | 13.18x | 1.58% | 64.69B | |
| 30.16x | 8x | 26.2x | 0.05% | 54.78B | |
| 36.79x | 6.53x | 19.51x | 0.88% | 53.49B | |
| 35.59x | 3.45x | 14.87x | -.--% | 45.98B | |
| 49.71x | 5.74x | 31.52x | -.--% | 42.94B | |
| -19.41x | 187.75x | -20.66x | -.--% | 40.08B | |
| 28.93x | 8.21x | 21.27x | 0.37% | 33.52B | |
| 27.67x | 5.83x | 15.12x | -.--% | 23.97B | |
| 32.66x | 5.97x | 20.09x | -.--% | 23.67B | |
| Average | 17.16x | 24.43x | 8.76x | 0.29% | 39.31B | |
| Weighted average by Cap. | 24.27x | 24.84x | 14.13x | 0.42% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- MDGL Stock
- Valuation Madrigal Pharmaceuticals, Inc.
Select your edition
All financial news and data tailored to specific country editions
